Author: Ura Takehiro Okuda Kenji Shimada Masaru
Publisher: MDPI
E-ISSN: 2076-393x|2|3|624-641
ISSN: 2076-393x
Source: Vaccines, Vol.2, Iss.3, 2014-07, pp. : 624-641
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.
Related content
Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer
By Norian Lyse A. James Britnie R. Griffith Thomas S.
Cancers, Vol. 3, Iss. 1, 2011-02 ,pp. :
By Gómez Carmen Elena Perdiguero Beatriz Sánchez-Corzo Cristina Sorzano Carlos Oscar S. Esteban Mariano
Viruses, Vol. 10, Iss. 1, 2017-12 ,pp. :
Replicon RNA Viral Vectors as Vaccines
Vaccines, Vol. 4, Iss. 4, 2016-11 ,pp. :
DNA Vaccines: Recent Developments and the Future
By Wahren Britta Liu Margaret A.
Vaccines, Vol. 2, Iss. 4, 2014-10 ,pp. :